Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- New nanomaterial maintains conductivity in three dimensions
- Students: Cast Homecoming Royalty votes by noon today
- Dean Michael Scarf to lead pre-law event on international law, evolution of law schools
- Meet local CEOs on social entrepreneurship field trip
- Show us your Snapchat skills: Enter design contest for chance to create CWRU geofilter, win prizes